688192 迪哲医药
盘后交易 05-13 15:00:00
资讯
新帖
简况
迪哲医药-U05月12日主力净流出728.0万元 散户资金买入
市场透视 · 05-12 07:21
迪哲医药-U05月12日主力净流出728.0万元 散户资金买入
迪哲医药-U涨5% 券商看好
智选洞察 · 05-09
迪哲医药-U涨5% 券商看好
2024年，医药生物板块人均薪酬高的10家企业揭晓
中国制药网 · 05-09
2024年，医药生物板块人均薪酬高的10家企业揭晓
迪哲医药61岁董事长张小林年薪超600万元，近一个月减持套现1亿元
瑞财经 · 05-09
迪哲医药61岁董事长张小林年薪超600万元，近一个月减持套现1亿元
【华西医药】迪哲医药：收入符合预期，差异化管线收获在即
华西研究 · 05-08
【华西医药】迪哲医药：收入符合预期，差异化管线收获在即
迪哲医药：董事长张小林减持182.70万股 占总股本0.3977%
21世纪经济报道 · 05-08
迪哲医药：董事长张小林减持182.70万股 占总股本0.3977%
迪哲医药(688192.SH)董事长张小林累计减持公司182.7万股
智通财经 · 05-08
迪哲医药(688192.SH)董事长张小林累计减持公司182.7万股
迪哲医药-U05月08日主力净流入93.7万元 散户资金抛售
市场透视 · 05-08
迪哲医药-U05月08日主力净流入93.7万元 散户资金抛售
迪哲医药-U05月07日遭主力抛售2808.6万元
市场透视 · 05-07
迪哲医药-U05月07日遭主力抛售2808.6万元
A股创新药概念午后持续下挫，百济神州跌近9%，荣昌生物、益方生物、一品红、信立泰、迪哲医药等多股跌超5%。
美港电讯 · 05-07
A股创新药概念午后持续下挫，百济神州跌近9%，荣昌生物、益方生物、一品红、信立泰、迪哲医药等多股跌超5%。
【创新药概念持续调整 百济神州跌近9%】午后创新药概念持续下挫，百济神州跌近9%，荣昌生物、益方生物、一品红、信立泰、迪哲医药等多股跌逾5%。
金融界 · 05-07
【创新药概念持续调整 百济神州跌近9%】午后创新药概念持续下挫，百济神州跌近9%，荣昌生物、益方生物、一品红、信立泰、迪哲医药等多股跌逾5%。
迪哲医药-U大跌5% 券商看好
智选洞察 · 05-07
迪哲医药-U大跌5% 券商看好
迪哲医药-U05月06日主力净流出629.9万元 散户资金买入
市场透视 · 05-06
迪哲医药-U05月06日主力净流出629.9万元 散户资金买入
中国银河：给予迪哲医药买入评级
证券之星 · 05-05
中国银河：给予迪哲医药买入评级
迪哲医药2025年一季度营收显著增长但需关注现金流与债务状况
证券之星 · 05-01
迪哲医药2025年一季度营收显著增长但需关注现金流与债务状况
迪哲医药（688192）2025年一季报简析：营收上升亏损收窄
证券之星 · 04-30
迪哲医药（688192）2025年一季报简析：营收上升亏损收窄
迪哲医药营收大涨294%，销售增加241人
时代财经 · 04-30
迪哲医药营收大涨294%，销售增加241人
迪哲医药一季度亏损减少至1.93万元
财中社 · 04-30
迪哲医药一季度亏损减少至1.93万元
两款独家抗癌药放量，无锡药企迪哲医药年营收大涨294%，销售增加241人几近翻倍
时代财经 · 04-30
两款独家抗癌药放量，无锡药企迪哲医药年营收大涨294%，销售增加241人几近翻倍
藏在迪哲医药财报中的三重惊喜
动脉网 · 04-30
藏在迪哲医药财报中的三重惊喜
加载更多
公司概况
公司名称：
迪哲(江苏)医药股份有限公司
所属行业：
医药制造业
上市日期：
2021-12-10
主营业务：
迪哲(江苏)医药股份有限公司的主营业务是公司是一家创新型生物医药企业，专注于恶性肿瘤、免疫性疾病领域创新疗法的研究、开发和商业化。公司的主要产品是抗肿瘤药物。
发行价格：
52.58
{"stockData":{"symbol":"688192","market":"SH","secType":"STK","nameCN":"迪哲医药","latestPrice":54.41,"timestamp":1747119600000,"preClose":52.23,"halted":0,"volume":4020681,"delay":0,"changeRate":0.0417,"floatShares":187000000,"shares":459000000,"eps":-1.7724,"marketStatus":"盘后交易","change":2.18,"latestTime":"05-13 15:00:00","open":53.65,"high":54.88,"low":52.73,"amount":218000000,"amplitude":0.0412,"askPrice":54.45,"askSize":65,"bidPrice":54.41,"bidSize":12,"shortable":0,"etf":0,"ttmEps":-1.7724,"tradingStatus":3,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1747186200000},"marketStatusCode":4,"adr":0,"adjPreClose":52.23,"symbolType":"stock_kcb","openAndCloseTimeList":[[1747099800000,1747107000000],[1747112400000,1747119600000]],"highLimit":57.45,"lowLimit":47.01,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":459412894,"isCdr":false,"pbRate":1354.07,"roa":"--","roe":"--","epsLYR":-2.04,"committee":-0.325444,"marketValue":24997000000,"turnoverRate":0.0215,"status":0,"afterMarket":{"amount":0,"volume":0,"close":54.41,"buyVolume":0,"sellVolume":0,"time":1747120660029,"indexStatus":"盘后交易 05-13 15:17:40","preClose":52.23},"floatMarketCap":10159000000},"requestUrl":"/m/hq/s/688192","defaultTab":"news","newsList":[{"id":"2534244255","title":"迪哲医药-U05月12日主力净流出728.0万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2534244255","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534244255?lang=zh_cn&edition=full","pubTime":"2025-05-12 15:21","pubTimestamp":1747034498,"startTime":"0","endTime":"0","summary":"05月12日, 迪哲医药-U股价跌7.36%，报收52.23元，成交金额3.3亿元，换手率3.34%，振幅6.07%，量比1.41。迪哲医药-U今日主力资金净流出728.0万元，上一交易日主力净流入615.0万元。该股近5个交易日下跌9.81%，主力资金累计净流出3457.8万元；近20日主力资金累计净流入4062.4万元，其中净流入天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250512173914a6dc07da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250512173914a6dc07da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2534123902","title":"迪哲医药-U涨5% 券商看好","url":"https://stock-news.laohu8.com/highlight/detail?id=2534123902","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534123902?lang=zh_cn&edition=full","pubTime":"2025-05-09 14:42","pubTimestamp":1746772940,"startTime":"0","endTime":"0","summary":"05月09日，迪哲医药-U股价大幅上涨，截至14点42分，迪哲医药-U上涨5.08%，报56.73元/股，成交2.19亿元，换手率2.11%。资金动向截止发稿，迪哲医药-U获得主力净流入734万元，其中超大单流入582万元，大单流入151万元。主营业务及业绩迪哲医药-U公司主营业务为创新药物的研发和产业化，高度重视员工的创新研发能力。最新财报显示，今年一季报，迪哲医药-U实现营业收入1.60亿元，同比增长96.32%，净利润为-1.93亿元，同比增长14.15%，基本每股收益为-0.46元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050914422694f17201&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050914422694f17201&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2534011483","title":"2024年，医药生物板块人均薪酬高的10家企业揭晓","url":"https://stock-news.laohu8.com/highlight/detail?id=2534011483","media":"中国制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534011483?lang=zh_cn&edition=full","pubTime":"2025-05-09 10:29","pubTimestamp":1746757765,"startTime":"0","endTime":"0","summary":"截至目前，A股 医药生物 板块2024年年报披露已完毕，与此同时，药企员工人均薪酬情况也浮出水面。根据数据统计，2024年，医药生物板块人均薪酬高的十家企业分别是 百济神州 、 迪哲医药 、 亚虹医药 、 益方生物 、 福瑞股份 、 盟科药业 、 艾力斯 、 诺诚健华 、 天智航 、 君实生物 。2024年公司归属于上市公司股东的净亏损3.84亿元，亏损幅度有所减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509103820a4778552&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509103820a4778552&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["000808.SH","06160","BK0239","163118","688192"],"gpt_icon":0},{"id":"2534650113","title":"迪哲医药61岁董事长张小林年薪超600万元，近一个月减持套现1亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2534650113","media":"瑞财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534650113?lang=zh_cn&edition=full","pubTime":"2025-05-09 09:33","pubTimestamp":1746754400,"startTime":"0","endTime":"0","summary":"公告显示，迪哲医药近日收到董事长兼首席执行官张小林出具的股份减持结果的告知函，截至2025 年5月7日收盘，张小林通过集中竞价累计减持了公司股份182.7万股，约占公司目前总股本0.4%，本次减持计划已实施完毕。据悉，本次减持期间为2025年4月3日～2025年5月7日，减持总金额为1亿元，减持原因为偿还借款等个人资金需求。业绩方面，2024年，迪哲医药实现营业收入3.60亿元，同比增长294.24%；归母净亏损约8.46亿元，上年同期亏损11.08亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505090935449753dead&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505090935449753dead&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2534911261","title":"【华西医药】迪哲医药：收入符合预期，差异化管线收获在即","url":"https://stock-news.laohu8.com/highlight/detail?id=2534911261","media":"华西研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534911261?lang=zh_cn&edition=full","pubTime":"2025-05-09 07:48","pubTimestamp":1746748137,"startTime":"0","endTime":"0","summary":"“华西研究”小程序全面升级！专业研值，一镜到底！华西医药公司发布2024年年报&2025年一季报：公司2024年度实现营业收入3.60亿元、归母净利润-8.46亿元，同比减亏23.63%、扣非归母净利润-8.99亿元，同比减亏22.56%。（二）投资建议调整公司2025-2026年盈利预测并新增2027年盈利预测，即预计 2025-2027年营业总收入分别为 7.15/12.35/24.13亿元，2025-2027年EPS分别为-1.28/-0.54/1.16元，对应2025年5月7日的53.72元/股收盘价，PE分别为-42/-99/46X，维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509075206a477583d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509075206a477583d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","159938","BK0239"],"gpt_icon":0},{"id":"2533725999","title":"迪哲医药：董事长张小林减持182.70万股 占总股本0.3977%","url":"https://stock-news.laohu8.com/highlight/detail?id=2533725999","media":"21世纪经济报道","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533725999?lang=zh_cn&edition=full","pubTime":"2025-05-08 17:12","pubTimestamp":1746695520,"startTime":"0","endTime":"0","summary":"南财智讯5月8日电，迪哲医药公告，董事长兼首席执行官张小林博士因偿还借款等个人资金需求，通过集中竞价交易方式减持182.70万股，占公司总股本0.3977%，减持价格区间为50.00至59.10元/股，减持总金额为10047.81万元。减持后，张小林博士持有公司股份548.40万股，占公司总股本1.1937%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508171316a476732c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508171316a476732c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2533597637","title":"迪哲医药(688192.SH)董事长张小林累计减持公司182.7万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2533597637","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533597637?lang=zh_cn&edition=full","pubTime":"2025-05-08 16:47","pubTimestamp":1746694042,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)发布公告，公司近日收到董事长兼首席执行官张小林博士出具的股份减持结果的告知函，截至2025年5月7日收盘，张小林博士通过集中竞价累计减持了公司股份182.7万股，占公司目前总股本0.3977%，本次减持计划已实施完毕。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1290794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2533598972","title":"迪哲医药-U05月08日主力净流入93.7万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2533598972","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533598972?lang=zh_cn&edition=full","pubTime":"2025-05-08 15:20","pubTimestamp":1746688822,"startTime":"0","endTime":"0","summary":"05月08日, 迪哲医药-U股价涨0.50%，报收53.99元，成交金额1.5亿元，换手率1.53%，振幅2.38%，量比0.64。迪哲医药-U今日主力资金净流入93.7万元，上一交易日主力净流出2808.6万元。该股近5个交易日下跌5.99%，主力资金累计净流出2879.5万元；近20日主力资金累计净流入2605.6万元，其中净流入天数为11日。|05月08日主力加仓幅度排名||#|股票简称|主力净额占比|#|*ST双成|8.61%|#|跨境通|7.99%|#|中百集团|7.29%|#|...|...|#2056|迪哲医药-U|0.01%|迪哲医药-U所在的化学制药行业，今日主力净流出8672万元，行业排名42/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508170535a6d7659a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508170535a6d7659a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2533670521","title":"迪哲医药-U05月07日遭主力抛售2808.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533670521","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533670521?lang=zh_cn&edition=full","pubTime":"2025-05-07 15:20","pubTimestamp":1746602459,"startTime":"0","endTime":"0","summary":"05月07日, 迪哲医药-U股价跌5.62%，报收53.72元，成交金额3.8亿元，换手率3.76%，振幅8.42%，量比1.82。迪哲医药-U今日主力资金净流出2808.6万元，上一交易日主力净流出629.9万元。该股近5个交易日下跌5.09%，主力资金累计净流出642.2万元；近20日主力资金累计净流出1511.1万元，其中净流出天数为10日。|05月07日主力加仓幅度排名||#|股票简称|主力净额占比|#|*ST精伦|9.01%|#|长华化学|6.32%|#|*ST国华|6.24%|#|...|...|#4488|迪哲医药-U|-0.28%|迪哲医药-U所在的化学制药行业，今日主力净流出5.40亿元，行业排名25/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507165652a4751be8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507165652a4751be8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2533623745","title":"A股创新药概念午后持续下挫，百济神州跌近9%，荣昌生物、益方生物、一品红、信立泰、迪哲医药等多股跌超5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2533623745","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533623745?lang=zh_cn&edition=full","pubTime":"2025-05-07 13:56","pubTimestamp":1746597395,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["688192","399300","BK4139","06978","06160","002294","BK1574","BK1588","BK0188","688331","BK1583","LU2328871848.SGD","LU1064130708.USD","688382","ONC","BK0028","BK0187","159982","LU1064131003.USD","BK1161","LU0307460666.USD","LU0588546209.SGD","BK1500","BK0183","BK0239","BK0196","300723","LU1969619763.USD","09995","LU2148510915.USD","688235","159992"],"gpt_icon":0},{"id":"2533253366","title":"【创新药概念持续调整 百济神州跌近9%】午后创新药概念持续下挫，百济神州跌近9%，荣昌生物、益方生物、一品红、信立泰、迪哲医药等多股跌逾5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2533253366","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533253366?lang=zh_cn&edition=full","pubTime":"2025-05-07 13:54","pubTimestamp":1746597245,"startTime":"0","endTime":"0","summary":"午后创新药概念持续下挫，百济神州跌近9%，荣昌生物、益方生物、一品红、信立泰、迪哲医药等多股跌逾5%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/07135450187475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["300723","BK1161","688192","BK4139","688382","BK1574","09995","BK0187","BK0196","LU2148510915.USD","LU1064131003.USD","BK0183","LU0588546209.SGD","002294","LU1064130708.USD","BK0028","06978","BK1588","BK1500","06160","LU1969619763.USD","LU2328871848.SGD","ONC","BK1583","BK0188","688331","688235","LU0307460666.USD","159992","BK0239"],"gpt_icon":0},{"id":"2533643753","title":"迪哲医药-U大跌5% 券商看好","url":"https://stock-news.laohu8.com/highlight/detail?id=2533643753","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533643753?lang=zh_cn&edition=full","pubTime":"2025-05-07 10:51","pubTimestamp":1746586262,"startTime":"0","endTime":"0","summary":"05月07日，迪哲医药-U股价大幅下跌，截至10点51分，迪哲医药-U下跌5.01%，报54.07元/股，成交1.89亿元，换手率1.82%，振幅6.71%。资金动向截止发稿，迪哲医药-U获得主力净流出2535万元，其中超大单流出2121万元，大单流出413万元。主营业务及业绩迪哲医药-U公司主营业务为创新药物的研发和产业化，高度重视员工的创新研发能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507105111a474c21c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507105111a474c21c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2533508707","title":"迪哲医药-U05月06日主力净流出629.9万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2533508707","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533508707?lang=zh_cn&edition=full","pubTime":"2025-05-06 15:20","pubTimestamp":1746516042,"startTime":"0","endTime":"0","summary":"05月06日, 迪哲医药-U股价跌1.71%，报收56.92元，成交金额2.2亿元，换手率2.04%，振幅5.09%，量比0.94。迪哲医药-U今日主力资金净流出629.9万元，上一交易日主力净流入159.5万元。该股近5个交易日下跌0.80%，主力资金累计净流入444.2万元；近20日主力资金累计净流入984.6万元，其中净流入天数为10日。|05月06日主力加仓幅度排名||#|股票简称|主力净额占比|#|*ST奥维|9.50%|#|*ST智胜|8.25%|#|天和磁材|6.83%|#|...|...|#3738|迪哲医药-U|-0.06%|迪哲医药-U所在的化学制药行业，今日主力净流入1.88亿元，行业排名36/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506165127a6d4c5e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506165127a6d4c5e8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2533729643","title":"中国银河：给予迪哲医药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2533729643","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533729643?lang=zh_cn&edition=full","pubTime":"2025-05-05 14:05","pubTimestamp":1746425125,"startTime":"0","endTime":"0","summary":"中国银河证券股份有限公司程培,闫晓松近期对迪哲医药进行研究并发布了研究报告《迪哲医药2024年年报及2025年一季报业绩点评：核心产品快速放量，创新管线接力布局》，给予迪哲医药买入评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050500001190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601881","688192"],"gpt_icon":0},{"id":"2532010877","title":"迪哲医药2025年一季度营收显著增长但需关注现金流与债务状况","url":"https://stock-news.laohu8.com/highlight/detail?id=2532010877","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532010877?lang=zh_cn&edition=full","pubTime":"2025-05-01 09:36","pubTimestamp":1746063362,"startTime":"0","endTime":"0","summary":"近期迪哲医药发布2025年一季报，证券之星财报模型分析如下：迪哲医药2025年一季度财务表现收入与利润情况根据迪哲医药发布的2025年一季报，公司营业总收入达到1.6亿元，同比上升96.32%。每股经营性现金流：-0.32元，同比减少3.94%。这表明公司在现金流管理和债务控制方面面临一定压力。总结迪哲医药在2025年一季度实现了营业总收入的显著增长，亏损有所收窄，但公司仍需密切关注现金流和债务状况，以确保长期稳健发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501094535a6cf89d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501094535a6cf89d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159399","688192"],"gpt_icon":0},{"id":"2532000090","title":"迪哲医药（688192）2025年一季报简析：营收上升亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2532000090","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532000090?lang=zh_cn&edition=full","pubTime":"2025-05-01 06:38","pubTimestamp":1746052733,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期迪哲医药发布2025年一季报。根据财报显示，迪哲医药营收上升亏损收窄。截至本报告期末，公司营业总收入1.6亿元，同比上升96.32%，归母净利润-1.93亿元，同比上升14.15%。本次财报公布的各项数据指标表现尚佳。持有迪哲医药最多的基金为鹏华医药科技股票A，目前规模为19.49亿元，最新净值1.3781，较上一交易日上涨1.61%，近一年上涨22.91%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050100004757.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192"],"gpt_icon":0},{"id":"2531170118","title":"迪哲医药营收大涨294%，销售增加241人","url":"https://stock-news.laohu8.com/highlight/detail?id=2531170118","media":"时代财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531170118?lang=zh_cn&edition=full","pubTime":"2025-04-30 15:33","pubTimestamp":1745998432,"startTime":"0","endTime":"0","summary":"财报数据显示，2024年及2025年一季度，迪哲医药的销售费用分别是4.45亿元、1.24亿元，上年同期分别是2.10亿元、0.92亿元；研发费用分别是7.24亿元、2.10亿元，上年同期分别是8.06亿元、2.05亿元。年报数据显示，截至2024年年底，迪哲医药的销售人员增至488人，较上年同期的247人增加近一倍。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430154625a46d55e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430154625a46d55e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192"],"gpt_icon":0},{"id":"2531720594","title":"迪哲医药一季度亏损减少至1.93万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531720594","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531720594?lang=zh_cn&edition=full","pubTime":"2025-04-30 12:04","pubTimestamp":1745985872,"startTime":"0","endTime":"0","summary":"4月29日，迪哲医药公布2025年一季报，公司营业收入为1.6亿元，同比上升96.3%；归母净利润自去年同期亏损2.24亿元变为亏损1.93亿元，亏损额有所减少；扣非归母净利润自去年同期亏损2.55亿元变为亏损2.19亿元，亏损额有所减少；经营现金流净额为-1.32亿元，同比下降4.4%；EPS为-0.4609元。截至一季度末，公司总资产18.05亿元，较上年度末增长5.0%；归母净资产为1846万元，较上年度末下降90.5%。文章来源：财中社迪哲医药一季度亏损减少至1.93万元","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430122935a46d23e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430122935a46d23e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2531722314","title":"两款独家抗癌药放量，无锡药企迪哲医药年营收大涨294%，销售增加241人几近翻倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2531722314","media":"时代财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531722314?lang=zh_cn&edition=full","pubTime":"2025-04-30 11:58","pubTimestamp":1745985489,"startTime":"0","endTime":"0","summary":"图片来源：图虫创意得益于两款独家抗癌创新药持续放量，迪哲医药2024年及2025年一季度营收均实现大幅增长，亏损进一步收窄。对于销售费用的大幅增长，迪哲医药在年报中解释称，主要系商业化团队扩张较快增加的人力成本及加大市场开拓力度的支出。年报数据显示，截至2024年年底，迪哲医药的销售人员增至488人，较上年同期的247人增加近一倍。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043011582094e869cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043011582094e869cd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192"],"gpt_icon":0},{"id":"2531258597","title":"藏在迪哲医药财报中的三重惊喜","url":"https://stock-news.laohu8.com/highlight/detail?id=2531258597","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531258597?lang=zh_cn&edition=full","pubTime":"2025-04-30 09:33","pubTimestamp":1745976780,"startTime":"0","endTime":"0","summary":"迪哲医药2024年财报显示，公司营业收入达3.6亿元，同比增长294%；2025年第一季度营收1.6亿元，同比增长96%。得益于提质增效策略，公司在研发、销售和管理等方面的费用控制显著，亏损额持续缩窄。2024年亏损同比减少24%，2025年Q1继续减亏14%。两款主要产品舒沃哲®（舒沃替尼片）和高瑞哲®（戈利昔替尼胶囊）已在中国获批并纳入医保，预计将进一步推动收入增长。此外，迪哲医药在2025年4月完成定增募集资金约18亿元，为其未来发展提供了强有力的支持。财务数据显示，公司的商业模型得到持续验证，亏损额逐年下降，预计未来将加速迈向盈亏平衡点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430100825974ae27d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430100825974ae27d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1747120661752,"stockEarnings":[{"period":"1week","weight":-0.0981},{"period":"1month","weight":0.038},{"period":"3month","weight":0.2616},{"period":"6month","weight":0.131},{"period":"1year","weight":0.2808},{"period":"ytd","weight":0.2595}],"compareEarnings":[{"period":"1week","weight":0.0275},{"period":"1month","weight":0.0405},{"period":"3month","weight":0.0154},{"period":"6month","weight":-0.0204},{"period":"1year","weight":0.0681},{"period":"ytd","weight":0.0052}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"迪哲(江苏)医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"8686人(较上一季度增加2.65%)","perCapita":"21496股","listingDate":"2021-12-10","address":"江苏省无锡市新吴区和风路26号汇融商务广场C栋404、405、416室","registeredCapital":"45941万元","survey":" 迪哲(江苏)医药股份有限公司的主营业务是公司是一家创新型生物医药企业，专注于恶性肿瘤、免疫性疾病领域创新疗法的研究、开发和商业化。公司的主要产品是抗肿瘤药物。","listedPrice":52.58},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迪哲医药(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迪哲医药(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迪哲医药,688192,迪哲医药股票,迪哲医药股票老虎,迪哲医药股票老虎国际,迪哲医药行情,迪哲医药股票行情,迪哲医药股价,迪哲医药股市,迪哲医药股票价格,迪哲医药股票交易,迪哲医药股票购买,迪哲医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迪哲医药(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迪哲医药(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}